Welcome to our dedicated page for Nexgel Wt Exp 120126 news (Ticker: NXGLW), a resource for investors and traders seeking the latest updates and insights on Nexgel Wt Exp 120126 stock.
NEXGEL, Inc. (NASDAQ: NXGL, warrants: NXGLW) regularly issues news and regulatory updates that highlight its activities in healthcare, beauty and over-the-counter (OTC) hydrogel products, contract manufacturing, and drug delivery initiatives. This news page aggregates those announcements so readers can review how the company describes its progress, partnerships and financial results over time.
Recent press releases have focused on quarterly financial results, where NEXGEL reports revenue, gross profit, operating expenses, net loss and non-GAAP measures such as EBITDA and Adjusted EBITDA. Management commentary in these releases discusses performance in contract manufacturing and consumer branded products, including references to partnerships with organizations like Cintas and STADA, and to consumer demand for brands such as Silly George within the company’s broader portfolio.
NEXGEL’s news flow also includes strategic and corporate developments. The company announced the spin-off of select drug delivery application assets into NexGelRx, an entity that will focus on prescription (Rx) drug delivery solutions using NEXGEL’s proprietary hydrogel technology. Follow-up news detailed strategic investments into NexGelRx from investors associated with Diesis Holdings, LLC and the appointment of a board observer and advisor with experience in reimbursement strategy and healthcare commercialization.
Other announcements cover capital markets transactions, such as registered direct offerings and concurrent private placements of common stock and warrants, as well as expanded partnerships like the agreement with STADA Arzneimittel AG, which includes non-dilutive capital to support product launches and marketing efforts in North America. NEXGEL also issues notices about upcoming earnings calls, conference presentations, and new investor presentations furnished via Form 8-K.
Investors and observers can use this news feed to follow NEXGEL’s own descriptions of its financial performance, hydrogel-based product initiatives, partnership activity and governance decisions, and to track how the company communicates its strategy and operations over time.
NEXGEL (NASDAQ:NXGL), a hydrogel products manufacturer, has expanded its partnership with STADA Arzneimittel AG for the North American market. The collaboration focuses on launching digestive enzyme formulas and solutions for scars and stretch marks.
As part of this strategic expansion, STADA will provide $1 million in non-dilutive capital to support NEXGEL's product launches and marketing initiatives. The partnership aims to bring innovative health solutions to North American consumers, leveraging NEXGEL's expertise in high-water-content hydrogel products and STADA's position as a European consumer health leader.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Interested participants can join via phone (U.S. Toll Free: 1-800-343-4849 or International: 1-203-518-9848) or webcast. A replay will be available through May 27, 2025, accessible by dialing +1-844-512-2921 (U.S.) or +1-412-317-6671 (International) with code 11159118. The webcast recording will be available for 90 days.
NEXGEL (NASDAQ: NXGL), a specialist in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, has announced its participation in the upcoming Planet MicroCap Showcase: Vegas 2025.
The company's Chief Executive Officer, Adam Levy, will deliver a presentation on Wednesday, April 23, 2025, at 9:30 a.m. PT in Track 4 - Loire at the Paris Hotel & Casino, Las Vegas. The event runs from April 22-24, 2025.
Investors interested in one-on-one meetings with Mr. Levy can arrange appointments through Planet Micro representatives or by contacting KCSA Strategic Communications at NEXGEL@KCSA.Com. A webcast of the presentation will be available through the company's investor relations website.
NEXGEL (NASDAQ: NXGL) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $3.04 million, up 181% year-over-year, while full-year revenue hit $8.69 million, increasing 112% compared to 2023.
Key Q4 metrics include gross profit of $1.13 million (37.2% margin) and net loss of $0.85 million. Full-year 2024 showed gross profit of $2.75 million (31.6% margin) with a net loss of $3.28 million. The company achieved over 100% revenue growth for the third consecutive year.
Notable developments include first shipments of SilverSeal® to Cintas, successful growth of the Silly George brand from $2M to $5M+ annual revenue, and partnership with STADA to launch Histasolv in North America. The company projects 2025 revenue guidance of $13 million and expects to achieve positive EBITDA during the year.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 24, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Interested participants can join via phone at 1-800-245-3047 (U.S. Toll Free) or 1-203-518-9765 (International). A replay will be available through April 3, 2025, accessible at 1-844-512-3921 (U.S.) or 1-412-317-6671 (International) using code 11158402. A webcast replay will be available for 90 days.
NEXGEL (NASDAQ: NXGL), a leading provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.
The company's Chief Executive Officer, Adam Levy, will deliver a presentation on Tuesday, March 25th, 2025, at 9:30 a.m. ET. The two-day conference will take place on March 25-26, 2025, and interested parties can access the webcast through the provided link.
Investors seeking one-on-one meetings with Mr. Levy can arrange appointments through iAccess representatives or by contacting KCSA Strategic Communications.
NEXGEL (NASDAQ: NXGL), a leading provider of medical and over-the-counter products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming Webull Consumer Virtual Webinar. The company's Chief Executive Officer, Adam Levy, will deliver a presentation on February 18, 2025, at 2:40 p.m. ET.
Investors interested in attending can access the webinar through the provided Webull zoom registration link. For those seeking one-on-one meetings with CEO Adam Levy, arrangements can be made through Webull representatives or by contacting KCSA Strategic Communications via email at NEXGEL@KCSA.Com.
NEXGEL (NASDAQ: NXGL) released its shareholder letter and guidance for 2024-2025, projecting Q4 2024 revenue of approximately $3.0 million and full-year 2024 revenue of $8.6 million, marking over 100% growth year-over-year for the third consecutive year. The company expects to generate at least $13 million in revenue for 2025 and achieve positive cash flow from operations.
The company operates in three core segments: contract manufacturing and white label, consumer products, and medical device development. Their consumer products division saw significant growth in 2024, particularly with the Silly George acquisition growing from $2 million to over $5 million in annual revenue. The company's partnership with Stada is progressing well, with their first product Histasolv exceeding projections and two additional product launches expected in H2 2025.
NEXGEL (NASDAQ: NXGL) has appointed Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. McGuire, who brings over 30 years of financial and public company experience, has been consulting with NEXGEL since September 2, 2024. He previously served as CFO for several private and public companies in healthcare, financial services, and manufacturing sectors, and was instrumental in guiding a biotech company to NYSE listing in July 2022.
The current CFO, Adam E. Drapczuk III, will transition to a consulting role with the company through his firm, Achieving Consulting Excellence, McGuire, a former Price Waterhouse CPA and Notre Dame graduate, will lead NEXGEL's finance functions as part of the executive management team. The appointment comes as NEXGEL, a provider of medical and OTC hydrogel products, continues to experience high growth.
FAQ
What is the current stock price of Nexgel Wt Exp 120126 (NXGLW)?
